Australian Public Assessment Report for Dinutuximab beta

The COG study established dinutuximab as a standard of care for maintenance treatment of high-risk neuroblastoma, so it was no longer feasible to continue with Study APN311-301 which was randomising patients to an arm which did not receive anti-GD2 immunotherapy. Protocol amendments were introduced and Study APN311-302 was initiated with the ... ................
................